The Cephalothin for Injection, cataloged under National Stock Number 6505-01-238-5627, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Glaxo Wellcome Inc. Government technical data includes 11 specifications, cited from the U.S. Government catalog. The record lists 1 manufacturer part number for this item, enabling identification through both NSN and commercial part number lookups. 1 additional reference document (drawings, advisory and superseded references) is recorded in the U.S. Government catalog. Current acquisition status: Active.
| Parameter | Value |
|---|---|
| NSN | 6505-01-238-5627 |
| Primary Part Number | NDC00173-0369-32 |
| Item Name | Cephalothin for Injection |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Glaxo Wellcome Inc |
| Status | ACTIVE |
| Administration | INTRAVENOUS |
| Primary Container Content Quantity | 2.000 GRAMS OF ACTIVE INGREDIENT G |
| Supplementary Features | MEDSEP ITEM FOR DOD,GLAXO INC |
| Secondary Container Type | TRAY |
| Medical Designation and Grade | UNITED STATES PHARMACOPEIA |
| Primary Container Type | BOTTLE, INFUSION |
| Physical Form | POWDER |
| Total Secondary Container Quantity | 10 |
| Primary Container Quantity Per Secondary Container | 10 TRAY |
| Active Medicament Medicinal Strength | 2.000 GRAMS CEPHALOTHIN EQUIVALENT G |
| Total Primary Container Quantity | 100 |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Part Number | Manufacturer |
|---|---|
| NDC00173-0369-32 PRIMARY | Glaxo Wellcome Inc (USA) |
| Reference | Meaning |
|---|---|
| SEFFIN | 5/1 Secondary reference Glaxo Wellcome Inc |
NSN 6505-01-238-5627 is a Cephalothin for Injection, manufactured by Glaxo Wellcome Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-238-5627 has 1 manufacturer part number on file: NDC00173-0369-32 (Glaxo Wellcome Inc).
Key specifications for NDC00173-0369-32: Administration: INTRAVENOUS; Primary Container Content Quantity: 2.000 GRAMS OF ACTIVE INGREDIENT G; Supplementary Features: MEDSEP ITEM FOR DOD,GLAXO INC; Secondary Container Type: TRAY. 11 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.